Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Not Yet Opened 10-08 16:00:00 EDT

12.87

+0.11

+0.82%

盘后12.87

+0.000.00%

19:31 EDT

High12.96	Low12.03	Vol677.78K
Open12.60	D1 Closing12.77	Amplitude7.29%
Mkt Cap365.67M	Tradable Cap338.16M	Total Shares28.41M
T/O8.63M	T/O Rate2.58%	Tradable Shares26.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":12.87,"timestamp":1791489600000,"preClose":12.765,"halted":0,"volume":677780,"hourTrading":{"tag":"盘后","latestPrice":12.87,"preClose":12.87,"latestTime":"19:31 EDT","volume":32426,"amount":416566.48,"timestamp":1791502317715,"change":0,"changeRate":0,"amplitude":0.019425},"delay":0,"changeRate":0.00822561692126899,"floatShares":26275300,"shares":28412537,"eps":-3.328942,"marketStatus":"Not Yet Opened","change":0.105,"latestTime":"10-08 16:00:00 EDT","open":12.6,"high":12.96,"low":12.03,"amount":8632658.83704,"amplitude":0.072855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.328942,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.765,"preHourTrading":{"tag":"盘前","latestPrice":12.44,"preClose":12.765,"latestTime":"09:29 EDT","volume":1400,"amount":17772.8936,"timestamp":1791466199999,"change":-0.325,"changeRate":-0.02546,"amplitude":0.054054},"postHourTrading":{"tag":"盘后","latestPrice":12.87,"preClose":12.87,"latestTime":"19:31 EDT","volume":32426,"amount":416566.48,"timestamp":1791502317715,"change":0,"changeRate":0,"amplitude":0.019425},"volumeRatio":0.855432,"impliedVol":0.9595,"impliedVolPercentile":0.336},"requestUrl":"/m/hq/s/ARCT/tweets","defaultTab":"tweets","newsList":[{"id":"2673370290","title":"Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673370290","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673370290?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:56","pubTimestamp":1791201360,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst maintained a Buy rating on Arcturus Therapeutics on October 2 and set a price target of $20.00. The company’s shares closed las...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499173","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499173?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:20","pubTimestamp":1790259612,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Ho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-teladoc-tdoc-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-teladoc-tdoc-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0980610538.SGD","LU0029864427.USD","BK4548","LU0310799852.SGD","LU1267930813.SGD","ZBH","BK4137","BK4585","TDOC","XBI","LU0006061336.USD","LU0310800379.SGD","BK4139","LU0648001328.SGD","LU0029874061.USD","IE00B7SZLL34.SGD","LU1861558580.USD","HCSG","BK4588","BK4581","LU1201861249.SGD","LU0128526141.USD","LU0708994859.HKD","BK4567","IE0002270589.USD","LU0211328371.USD","LU0792757196.USD","BK4167","LU0889566641.SGD","IE00B19Z3B42.SGD","ARCT","LABU","BK4082","LU1861559042.SGD","BK4566","BK4504","LU1267930490.SGD","LU0130517989.USD","LU1267930573.SGD","XLV","LU0130102774.USD","BK4534","LU0477156953.USD","LU0128525929.USD","LU0211327993.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669695014","title":"Arcturus Therapeutics Holdings Inc : Btig Cuts Target Price to $20 from $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2669695014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669695014?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:47","pubTimestamp":1790243275,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0N1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669446870","title":"US Research Roundup-Autozone, General Mills, JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2669446870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669446870?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:23","pubTimestamp":1790238235,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Autozone, General Mills, JPMorganSept 24 (Reuters)-Wall Street securities analysts revised their ratings and price targets for several US-listed companies, including AutoZone, Gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCD","ALKT","LBO","DOCK","IYT","CCNE","JPMO","CSX","KBWB","MTB","P","AJG","COLB","HBAN","BANC","SHPP","ARCT","IAT","EFSC","CCL","KEY","CWBC","IYG","CATY","BCML","CRWV","ALMR","FLG","AVBH","CFR","JPM","AZO","GIS","DBX","FHN","HOPE","ARES","AX","CG","FITB","AMC","JPO","BOKU.UK","CFG","CRWU","BAC","FIBK","BOKF","EWBC","AUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436467","title":"Arcturus Agrees to Buy myNEO, Reports Interim Liver Disorder Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436467","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436467?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:29","pubTimestamp":1790195340,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings agreed to acquire the artificial-intelligence drug discovery company myNEO and reported interim data from a phase 2 trial of a treatment for a metabolic liver disorder.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435012","title":"Arcturus Says ARCT-810 Phase 2 Interim Data in OTC Deficiency Show Safety, Biomarker Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435012","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435012?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:01","pubTimestamp":1790193696,"startTime":"0","endTime":"0","summary":"Arcturus says ARCT-810 Phase 2 interim data in OTC deficiency show safety, biomarker improvementArcturus reported interim Phase 2 data showing ARCT-810 was generally safe, with fasting ammonia maintai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL2MQZzN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669743504","title":"Arcturus Therapeutics - to Buy Myneo to Improve Mrna Design Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2669743504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669743504?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:01","pubTimestamp":1790193695,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0VV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669350674","title":"Arcturus Therapeutics - Arct-810 Generally Safe and Well Tolerated in Ongoing Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669350674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669350674?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:01","pubTimestamp":1790193695,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0VV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669069435","title":"Arcturus Therapeutics - Announces Encouraging Interim Phase 2 Results from Arct-810 in Otc Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2669069435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669069435?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:01","pubTimestamp":1790193695,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668263019","title":"Arcturus to Present Phase 2 ARCT-810 Clinical Data in OTC Deficiency on Sept. 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2668263019","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668263019?lang=en_us&edition=fundamental","pubTime":"2026-09-18 21:01","pubTimestamp":1789736478,"startTime":"0","endTime":"0","summary":"Arcturus to present Phase 2 ARCT-810 clinical data in OTC deficiency on Sept. 23Arcturus scheduled a virtual event for Sept. 23, 2026 to present Phase 2 data for ARCT-810 in OTC deficiency.Results hav","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL6rNVMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668389926","title":"Arcturus Therapeutics to Present Ornithine Transcarbamylase (Otc) Deficiency Phase 2 Clinical Data and Provide Update on Mrna Liver Therapeutics Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2668389926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668389926?lang=en_us&edition=fundamental","pubTime":"2026-09-18 21:00","pubTimestamp":1789736401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA51RLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560219","title":"Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560219","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560219?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:05","pubTimestamp":1789038319,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Citi maintained a Hold rating on Arcturus Therapeutics, with a price target of $8.00. The company’s shares clo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-hold-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-hold-rating-on-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389543","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664389543?lang=en_us&edition=fundamental","pubTime":"2026-09-02 12:30","pubTimestamp":1788323420,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-and-eyepoint-pharmaceuticals-eypt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-and-eyepoint-pharmaceuticals-eypt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU2324357040.USD","BK4137","LABU","BK4581","BK4007","EYPT","LU0128526141.USD","LU0889565916.HKD","LU0029874061.USD","BK4585","XLV","HCSG","XBI","BK4139","LU0320765992.SGD","ARCT","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888177","title":"Arcturus Therapeutics to Present at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888177","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888177?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:01","pubTimestamp":1788206499,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics to present at H.C. Wainwright Global Investment ConferenceArcturus Therapeutics will join a series of investor conferences in September 2026, starting with Wells Fargo’s Healthca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLb6z4sZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1506573853.SGD","LU1668664300.SGD","LU0128525689.USD","LU2417539215.USD","LU0162691827.USD","LU2456880835.USD","IE00BSNM7G36.USD","LU0320765646.SGD","BK4534","LU1144417596.USD","LU2236285917.USD","TFNS","BK4588","LU0310800965.SGD","LU0130102774.USD","FTXO","LU2462157665.USD","BK4566","LU0648001328.SGD","BK4585","BK4139","LU0203345920.USD","BK4504","LU0314106906.USD","LU0477156953.USD","LU1162221912.USD","LU1074936037.SGD","LU1791807156.HKD","LU1267930227.SGD","LU2360032135.SGD","BK4207","LU0072461881.USD","LU0203347892.USD","ARCT","LU1244550577.SGD","LU0980610538.SGD","LU1366192091.USD","LU1244550221.USD","LU1244550494.USD","LU2125154778.USD","LU2125154935.USD","LU0106831901.USD","LU0052756011.USD","LU0098860793.USD","LU0130517989.USD","LU1201861249.SGD","BK4559","IYF","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662716124","title":"Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662716124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662716124?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:55","pubTimestamp":1787745335,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00. According to TipRanks, Walsh i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-their-buy-rating-for-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-their-buy-rating-for-arcturus-therapeutics-arct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660893052","title":"Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660893052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660893052?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:20","pubTimestamp":1787224836,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arcturus-therapeutics-arct-equipmentshare-com-inc-eqpt-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arcturus-therapeutics-arct-equipmentshare-com-inc-eqpt-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EQPT","NA","BK4141","TRAX","ARCT","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911401","title":"Analysts’ Opinions Are Mixed on These NA Stocks: Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Therapeutics (ARCT) and Ceribell, Inc. (CBLL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911401","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911401?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:40","pubTimestamp":1786462820,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-na-stocks-cardinal-infrastructure-group-inc-cdnl-arcturus-therapeutics-arct-and-ceribell-inc-cbll-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-na-stocks-cardinal-infrastructure-group-inc-cdnl-arcturus-therapeutics-arct-and-ceribell-inc-cbll-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CDNL","BK4082","BK4141","BK4129","ARCT","CBLL","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657966308","title":"Arcturus Therapeutics Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657966308","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657966308?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050109,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings SummaryArcturus Therapeutics Holdings IncARCT.OQreported a quarterly adjusted loss of 84 cents per share for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657060","title":"Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657060?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:12","pubTimestamp":1786047154,"startTime":"0","endTime":"0","summary":"Arcturus Q2 revenue falls sharply on CSL Seqirus deal endOverviewMessenger RNA medicines company's Q2 revenue fell sharply yr/yr due to CSL Seqirus collaboration terminationQ2 net loss widened yr/yr, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","LGHT","MRNX","BK7501","WDNA","BK4532","BK7511","BK4551","ARCT","BK4139","MRNA","BK7067","BK4534","BK4568","BK4548","IDNA","BK4533","BK4501","MRNY","CSL.AU","BK4588","BK4585","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652763","title":"Arcturus Therapeutics Q2 Net Income USD -23.785 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652763","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652763?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics Q2 Net Income USD -23.785 MillionAug 06 (Reuters) - Arcturus Therapeutics Q2 operating income USD -25.545 million.Q2 basic EPS USD -0.84Q2 operating expenses USD 28.504 millionQ2 collaboration revenue USD 880 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXBKKQBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.1766},{"period":"3month","weight":0.8465},{"period":"6month","weight":0.5395},{"period":"1year","weight":-0.3929},{"period":"ytd","weight":1.0995}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.084619},{"month":2,"riseRate":0.538462,"avgChangeRate":0.016903},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.051078},{"month":4,"riseRate":0.615385,"avgChangeRate":0.111259},{"month":5,"riseRate":0.538462,"avgChangeRate":0.081426},{"month":6,"riseRate":0.571429,"avgChangeRate":0.011692},{"month":7,"riseRate":0.5,"avgChangeRate":0.079293},{"month":8,"riseRate":0.571429,"avgChangeRate":0.178945},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.053888},{"month":10,"riseRate":0.357143,"avgChangeRate":-0.076551},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033635},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.064746}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction